Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

• Published in: Journal of experimental & clinical cancer research Vol. 40; no. 1; pp. 328 - 17
• Main Authors: Zhou, Jing, Ji, Qing, Li, Qi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18.10.2021; BioMed Central; BMC
• Subjects: Analysis; Animals; Anti-epidermal growth factor receptor targeted therapies; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Cancer; Cancer therapies; Care and treatment; Cell growth; Clinical Decision-Making; Clinical Trials as Topic; Colorectal cancer; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - etiology; Colorectal Neoplasms - metabolism; Cytotoxicity; Development and progression; Disease Management; Drug Development; Drug resistance; Drug Resistance, Neoplasm - drug effects; Efficiency; Energy Metabolism - drug effects; Epidermal growth factor; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; ErbB Receptors - metabolism; Feedback; Gene Amplification; Gene mutations; Genetic aspects; Health aspects; Humans; Insulin-like growth factors; Kinases; Ligands; Medical prognosis; Melanoma; Metabolism; Metastasis; Metastatic colorectal cancer; Microsatellite Instability; Molecular Targeted Therapy - adverse effects; Molecular Targeted Therapy - methods; Monoclonal antibodies; Mutation; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - etiology; Neovascularization, Pathologic - metabolism; Phosphorylation; Protein Binding; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Proteins; Reversal strategies; Review; Signal Transduction - drug effects; Treatment Outcome; Tumor Microenvironment - drug effects; Tumors; Vascular endothelial growth factor; Reversal strategies; Anti-epidermal growth factor receptor targeted therapies; Drug resistance; Metastatic colorectal cancer

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therap...